MIV-150 is an NNRTI (non-nucleoside reverse transcriptase inhibitor) used for the inhibition of HIV-1 and HIV-2 infection; it effectively inactivates free virus and demonstrates high efficacy against HIV strains resistant to other marketed antiretrovirals such as nevirapine, delavirdine, and efavirenz; additionally, resistance to MIV-150 develops more slowly compared to other anti-HIV drugs.